Eisai Co., Ltd: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Eisai's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Eisai over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark Eisai's performance against key rivals in the prescription pharmaceutical sector
* See how the loss of patent protection on Eisai's blockbuster products Aricept and Pariet/AcipHex will impact Eisai's sales performance
* Evaluate Eisai's long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma
[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 7
Eisai: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 11
Chapter 3 Quarterly news update 17
Latest comment 17
Latest news 19
Chapter 4 Company introduction 24
Key findings 24
Background 25
Key corporate developments 25
M&A history 25
Chapter 5 Company sales 27
Key findings 27
Prescription pharmaceutical sales and growth rate analysis, 2003–15 28
Product analysis 29
Therapy area analysis 35
Geographic analysis 37
Launch/core/expiry analysis 39
Molecule type analysis 45
Externalization analysis 47
Chapter 6 Company financials 49
Key findings 49
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 50
Operating costs and profit analysis 51
Chapter 7 Key products 56
Overview 56
Chapter 8 Appendix 72
References 72
Abbreviations 72
Exchange rates 73
About Datamonitor 74
Datamonitor consulting 74
Disclaimer 76


TABLE OF TABLES
Table 1: Eisai – PharmaVitae forecasts at a glance 8
Table 2: Eisai product portfolio overview ($m), 2003–09 30
Table 3: Eisai product portfolio overview ($m), 2009–15 32
Table 4: Eisai prescription pharmaceutical sales by therapy area ($m), 2009–15 36
Table 5: Eisai prescription pharmaceutical sales by geographic region ($m), 2009–15 38
Table 6: Eisai launch portfolio overview ($m), 2009–15 40
Table 7: Eisai core portfolio overview ($m), 2009–15 41
Table 8: Eisai expiry portfolio overview ($m), 2009–15 42
Table 9: Eisai generics portfolio overview ($m), 2009–15 43
Table 10: Eisai prescription pharmaceutical sales by molecule type ($m), 2009–15 46
Table 11: Eisai prescription pharmaceutical sales by source ($m), 2009–15 48
Table 12: Total Eisai sales by business unit ($m), 2003–09 50
Table 13: Eisai operating revenue/cost analysis ($m), 2003–09 52
Table 14: Eisai operating cost ratio analysis (% of total revenues), 2003–09 53
Table 15: Eisai operating cost ratio analysis (% of total revenues), 2009–15 54
Table 16: Eisai operating revenue/cost analysis ($m), 2009–15 55
Table 17: Eisai Key products overview 56
Table 18: Aricept: overview 58
Table 19: Aricept: sales forecast ($m), 2009–15 59
Table 20: Methycobal: overview 61
Table 21: Methycobal: sales forecast ($m), 2009–15 62
Table 22: Humira: overview 64
Table 23: Humira: sales forecast ($m), 2009–15 65
Table 24: Pariet/Aciphex: overview 67
Table 25: Pariet/Aciphex: sales forecast ($m), 2009–15 68
Table 26: E5564: overview 70
Table 27: E5564: sales forecast ($m), 2009–15 71
Table 28: Exchange rates, 2010 73


TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Eisai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 6
Figure 3: Eisai’s financial performance ($m), 2003–15 7
Figure 4: Sales decline of Eisai’s blockbuster drugs ($m), 2009–15 9
Figure 5: Eisai SWOT analysis 11
Figure 6: Eisai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 28
Figure 7: Eisai key product sales ($m), 2003–15 29
Figure 8: Eisai key sales growth drivers and resistors ($m), 2003–09 31
Figure 9: Eisai key sales growth drivers and resistors ($m), 2009–15 33
Figure 10: Eisai prescription pharmaceutical sales by therapy area ($m), 2003–15 35
Figure 11: Eisai prescription pharmaceutical sales by geographic region ($m), 2003–15 37
Figure 12: Eisai launch/core/expiry configuration ($m), 2009–15 44
Figure 13: Eisai prescription pharmaceutical sales by molecule type ($m), 2003–15 45
Figure 14: Eisai prescription pharmaceutical sales by source ($m), 2003-15 47
Figure 15: Eisai operating revenue/cost analysis ($m), 2003–15 51
Figure 16: Aricept sales by geography ($m), 2003–15 59
Figure 17: Methycobal sales by geography ($m), 2003–15 62
Figure 18: Humira sales by geography ($m), 2003–15 65
Figure 19: Pariet/Aciphex sales by geography ($m), 2003–15 68
Figure 20: E5564 sales by geography ($m), 2003–15 71


[Inhaltsverzeichnis ausblenden]